Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDN Augmentation for Breakthrough Depression
NCT01874951Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Jun 2013; status: completed.
02
Drugs
naltrexone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01874951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01874951.